During the Open Innovations Forum of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, the R-Pharm group (official representative of the world leader in genomics Illumina in Russia) and AstraZeneca signed a memorandum of intentions for development cooperation in the fight against cancer.
Companies are striving to ensure accessibility for Russian patients of an innovative comprehensive study of gene panels (molecular tumor profiling), in which mutations are associated with the choice of therapy, a new generation sequencing method (NGS) based on leading molecular genetic laboratories. Participants will also promote the appearance on the market of registered Russian-made test systems for analyzing gene panels and increasing the accessibility of molecular genetic testing for patients as part of the transition to paying for diagnostics in order to improve the quality of treatment and life of Russian patients through the use of advanced “targeted” approaches in chemotherapy.
At the moment, in Russia, there is not a single validated and registered solution that allows the analysis of gene panels by the NGS (molecular tumor profiling) method. Sergey Tsyb, First Deputy Minister of Industry and Trade, commented:
“The signing of the memorandum is a vivid example of unlocking the potential of the Russian scientific and technical industry in the field of medicine and the interest of leading international and Russian pharmaceutical companies in investing in the development and production of domestic innovative methods of molecular genetic diagnostics. I am sure that the agreement will increase the availability of targeted cancer therapy for Russian patients.”